ASKA Pharmaceutical Co., Ltd. reported consolidated earnings results for the six months ended September 30, 2017. For the six months, the company reported net sales of USD 227.7 million against USD 221.0 million a year ago. Operating income was USD 17.0 million against USD 12.1 million a year ago. Profit attributable to owners of parent was USD 14.9 million against USD 11.5 million a year ago.

For the year ending March 31, 2018, the company expects consolidated net sales of USD 454.5 million, operating income of USD 18.2 million, profit attributable to owners of parent of USD 16.4 million.